NCT04708418 2026-03-18
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
Clinical Trials
81 trialsNCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
NCT04609566 2026-03-16
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Seagen Inc.
Phase 2 Completed
NCT06771544 2026-03-10
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
University of California, Irvine
Phase 2 Recruiting
NCT05926960 2026-03-09
PORTSIDE
Pfizer
Phase 2 Terminated
NCT06961006 2026-03-09
INTerpath-012
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07448831 2026-03-09
NeoSenti
Universitair Ziekenhuis Brussel
Phase 2 Recruiting
NCT06984328 2026-03-03
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
Genmab
Phase 2 Active not recruiting
NCT06999980 2026-02-19
Neo IRENIE
Melanoma Institute Australia
Phase 2 Recruiting
NCT02816021 2026-02-17
Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05155033 2026-02-17
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07376317 2026-01-29
OTIMAS
Instituto do Cancer do Estado de São Paulo
Phase 2 Active not recruiting
NCT07349303 2026-01-21
NEOPRIME
Vastra Gotaland Region
Phase 2 Recruiting
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT03873818 2026-01-09
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04207086 2025-12-16
Neo PeLe
Melanoma Institute Australia
Phase 2 Active not recruiting
NCT03595683 2025-12-08
Pembrolizumab and EDP1503 in Advanced Melanoma
University of Chicago
Phase 2 Terminated
NCT03897881 2025-12-03
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
ModernaTX, Inc.
Phase 2 Active not recruiting
NCT04570332 2025-11-26
SPOTLIGHT203
Highlight Therapeutics
Phase 2 Completed
NCT04955743 2025-11-24
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Yale University
Phase 2 Terminated
NCT05282901 2025-11-24
PLUME
Institut Curie
Phase 2 Active not recruiting
NCT02621021 2025-11-21
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT04796194 2025-11-20
ATLAS-IT-05
Lytix Biopharma AS
Phase 2 Completed
NCT02965716 2025-11-18
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07223424 2025-11-10
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
NCT05309421 2025-09-22
A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma
Evaxion Biotech A/S
Phase 2 Active not recruiting
NCT06906822 2025-09-18
PlugIN
Grupo Español Multidisciplinar de Melanoma
Phase 2 Recruiting
NCT02681549 2025-08-07
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Yale University
Phase 2 Completed
NCT05308901 2025-07-25
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
Providence Health & Services
Phase 2 Active not recruiting
NCT05304546 2025-07-22
MK3475-C01
Sheba Medical Center
Phase 2 Completed
NCT03645928 2025-06-19
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Iovance Biotherapeutics, Inc.
Phase 2 Recruiting
NCT02743819 2025-06-10
Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma
University of Chicago
Phase 2 Active not recruiting
NCT04830124 2025-06-10
ARTISTRY-6
Mural Oncology, Inc
Phase 2 Terminated
NCT06099782 2025-04-20
MK-3475A-F11
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT06797297 2025-04-04
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Recruiting
NCT02644369 2025-03-26
INSPIRE
University Health Network, Toronto
Phase 2 Active not recruiting
NCT05913388 2025-03-11
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Providence Health & Services
Phase 2 Recruiting
NCT04032704 2025-03-10
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Seagen Inc.
Phase 2 Terminated
NCT03757689 2025-02-11
Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma
Abramson Cancer Center at Penn Medicine
Phase 2 Active not recruiting
NCT04114136 2025-02-10
Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies
University of Pittsburgh
Phase 2 Recruiting
NCT02500576 2025-01-15
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT04068181 2025-01-07
Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07).
Amgen
Phase 2 Completed
NCT03341143 2024-10-30
Fecal Microbiota Transplant (FMT) in Melanoma Patients
University of Pittsburgh
Phase 2 Completed
NCT06651151 2024-10-26
NeoLIPA
Oslo University Hospital
Phase 2 Recruiting
NCT05764395 2024-10-10
Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors
Vanderbilt-Ingram Cancer Center
Phase 2 Suspended
NCT03476174 2024-10-02
Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma
Hoosier Cancer Research Network
Phase 2 Terminated
NCT03448666 2024-09-23
ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases
European Institute of Oncology
Phase 2 Withdrawn
NCT04768881 2024-08-23
Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Karyopharm Therapeutics Inc
Phase 2 Terminated
NCT03620019 2024-08-12
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT04152863 2024-08-06
V937-011
Merck Sharp & Dohme LLC
Phase 2 Terminated